Citius Pharma Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 22


  • Stock Symbol
  • CTXR

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.61
  • (As of Tuesday Closing)

Citius Pharma General Information


Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Contact Information

Formerly Known As
Citius Pharmaceuticals, Trailone, Inc., Trailone, Incorporation
Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Corporate Office
  • 11 Commerce Drive
  • First Floor
  • Cranford, NJ 07016
  • United States
+1 (908) 000-0000

Citius Pharma Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Citius Pharma Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.61 $0.62 $0.60 - $1.40 $110M 181M 1.52M -$0.24

Citius Pharma Financials Summary

In Thousands,
TTM 31-Mar-2024 FY 2023 30-Sep-2023 FY 2022 30-Sep-2022 FY 2021 30-Sep-2021
EV 123,439 76,574 130,098 182,337
Revenue 0 0 0 0
EBITDA (36,518) (32,952) (33,136) (23,141)
Net Income (36,199) (32,543) (33,641) (23,054)
Total Assets 90,711 103,611 113,999 142,429
Total Debt 375 481 678 855
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Citius Pharma Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Citius Pharma‘s full profile, request access.

Request a free trial

Citius Pharma Comparisons

HQ Location
Total Raised
Post Valuation
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescr
Cranford, NJ
22 As of 2023
00000000 000.00


iam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo con
0000 000000000
San Francisco, CA
0 As of 0000
000000000000 0000


aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volu
0000 000000000
Emeryville, CA
000 As of 0000
00.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Citius Pharma Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adynxx Formerly VC-backed San Francisco, CA 0 0000 000000000000 0000
Zogenix Formerly VC-backed Emeryville, CA 000 00000 000000&0 00000
Acorda Therapeutics Formerly VC-backed Ardsley, NY 000 00000 000000&0
Exonate Venture Capital-Backed Cambridge, United Kingdom 00 00.000 00000000000 00.000
Ardelyx Formerly VC-backed Fremont, CA 000 00000 000000000 00 00000
You’re viewing 5 of 36 competitors. Get the full list »

Citius Pharma Patents

Citius Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220062390-A1 Methods of treating cancer Pending 26-Aug-2020 000000000 0
EP-4204008-A1 Combination for use in methods of treating cancer Pending 26-Aug-2020 000000000

Citius Pharma Executive Team (10)

Name Title Board Seat Contact Info
Jaime Bartushak Chief Financial Officer & Chief Business Officer
Gary Talarico Executive Vice President, Operations
Jay Wadekar Senior Vice President, Business Strategy
Paul Sowyrda Vice President, Business Development & Market Intelligence
Ilanit Allen Vice President, Corporate Communications and Investor Relations
You’re viewing 5 of 10 executive team members. Get the full list »

Citius Pharma Board Members (8)

Name Representing Role Since
Carol Webb Citius Pharma Board Member 000 0000
Dennis McGrath Self Board Member 000 0000
Eugene Holuka MD Citius Pharma Board Member 000 0000
Leonard Mazur Self Co-Founder, Chief Executive Officer & Chairman of the board 000 0000
Myron Holubiak Self Co-Founder & Executive Vice Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Citius Pharma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Citius Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Citius Pharma‘s full profile, request access.

Request a free trial

Citius Pharma Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) 07-Sep-2021 000000000 0000 Buildings and Property 00000 000
Leonard-Meron Biosciences 04-Apr-2016 0000000000 Biotechnology 0000000 0
Trail One 12-Sep-2014 Merger/Acquisition 00.000 Automotive
To view Citius Pharma’s complete investments and acquisitions history, request access »

Citius Pharma Subsidiaries (1)

Company Name Industry Location Founded
Citius Oncology Biotechnology Cranford, NJ
To view Citius Pharma’s complete subsidiaries history, request access »

Citius Pharma ESG

Risk Overview

Risk Rating

Updated March, 01, 2024

34.93 | High Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,191






00 of 921






00 of 452




To view Citius Pharma’s complete esg history, request access »

Citius Pharma FAQs

  • When was Citius Pharma founded?

    Citius Pharma was founded in 2007.

  • Who is the founder of Citius Pharma?

    Leonard Mazur, Geoffrey Clark MD, and Reinier Beeuwkes Ph.D are the founders of Citius Pharma.

  • Who is the CEO of Citius Pharma?

    Leonard Mazur is the CEO of Citius Pharma.

  • Where is Citius Pharma headquartered?

    Citius Pharma is headquartered in Cranford, NJ.

  • What is the size of Citius Pharma?

    Citius Pharma has 22 total employees.

  • What industry is Citius Pharma in?

    Citius Pharma’s primary industry is Pharmaceuticals.

  • Is Citius Pharma a private or public company?

    Citius Pharma is a Public company.

  • What is Citius Pharma’s stock symbol?

    The ticker symbol for Citius Pharma is CTXR.

  • What is the current stock price of Citius Pharma?

    As of 18-Jun-2024 the stock price of Citius Pharma is $0.61.

  • What is the current market cap of Citius Pharma?

    The current market capitalization of Citius Pharma is $110M.

  • Who are Citius Pharma’s competitors?

    Adynxx, Zogenix, Acorda Therapeutics, Exonate, and Ardelyx are some of the 36 competitors of Citius Pharma.

  • What is Citius Pharma’s annual earnings per share (EPS)?

    Citius Pharma’s EPS for 12 months was -$0.24.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »